Navigation Links
Phase IIb Study of Vanoxerine Shows Strong Safety and Statistically Significant Efficacy Signals for Treatment of Atrial Fibrillation
Date:11/18/2013

DALLAS, Nov. 18, 2013 /PRNewswire/ -- ChanRx, a pharmaceutical company developing medicines for cardiovascular diseases, today announced positive safety and statistically significant efficacy data from a Phase IIb study of vanoxerine (GBR-12909), a drug in development for the treatment of atrial fibrillation. The data were presented yesterday at the American Heart Association 2013 Scientific Sessions.

"Atrial fibrillation affects millions of patients in the US annually, causing substantial morbidity," said Peter Kowey, MD, Professor of Medicine & Pharmacology, Jefferson School of Medicine and Lankenau Institute for Medical Research. "Currently, drugs that correct this arrhythmia are inadequate and carry safety risks including life threatening arrhythmias, long-term toxicity and liver failure. Both the patients with this condition and the physicians treating them could benefit greatly from a drug that could safely treat this arrhythmia."

In the randomized, placebo-controlled trial, 104 patients presenting with symptomatic atrial fibrillation or atrial flutter of recent onset were assigned to one of three doses of vanoxerine or placebo. Vanoxerine was found to be well tolerated at all doses.  Importantly, no episodes of monomorphic or polymorphic ventricular tachycardia were seen. Ventricular tachycardia is a potentially life-threatening arrhythmia that can lead to sudden death. The majority of currently marketed drugs used for atrial fibrillation have a risk of polymorphic ventricular tachycardia.

"Historically, drugs to treat atrial fibrillation have failed, not because they are ineffective, but because they have significant safety issues," noted Arthur "Buzz" Brown, MD, PhD, founder and CEO of ChanTest and founder and CSO of ChanRx. "Thus far, the clinical data showing a lack of pro-arrhythmic effects for vanoxerine are extremely promis
'/>"/>

SOURCE ChanRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... ALBANY, New York , July 25, 2014 /PRNewswire/ ... published by Transparency Market Research "Global and China Insulin ... Insulin) - Industry Analysis, Size, Share, Growth, Trends and ... insulin market was valued at USD 19.99 billion in ... of 6.1% from 2013 to 2019 to reach USD ...
(Date:7/25/2014)... July 25, 2014  IDEXX Laboratories, Inc. (NASDAQ: ... second quarter of 2014 increased 11% versus the prior ... for the second quarter of 2014 versus the ... changes in distributor inventory 2 . Earnings per diluted ... increased 11% from the prior year period to $1.10."In ...
(Date:7/25/2014)... Leading events organizer UBM Live announces ... seventh year to São Paulo, Brazil ... The event will co-locate with Food Ingredients South America (FiSA), ... point for the pharmaceutical industry.      (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ... sales are now exploring the South America ...
Breaking Medicine Technology:Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4IDEXX Laboratories Announces Second Quarter Results 2IDEXX Laboratories Announces Second Quarter Results 3IDEXX Laboratories Announces Second Quarter Results 4IDEXX Laboratories Announces Second Quarter Results 5IDEXX Laboratories Announces Second Quarter Results 6IDEXX Laboratories Announces Second Quarter Results 7IDEXX Laboratories Announces Second Quarter Results 8IDEXX Laboratories Announces Second Quarter Results 9IDEXX Laboratories Announces Second Quarter Results 10IDEXX Laboratories Announces Second Quarter Results 11IDEXX Laboratories Announces Second Quarter Results 12IDEXX Laboratories Announces Second Quarter Results 13IDEXX Laboratories Announces Second Quarter Results 14IDEXX Laboratories Announces Second Quarter Results 15IDEXX Laboratories Announces Second Quarter Results 16IDEXX Laboratories Announces Second Quarter Results 17IDEXX Laboratories Announces Second Quarter Results 18IDEXX Laboratories Announces Second Quarter Results 19IDEXX Laboratories Announces Second Quarter Results 20IDEXX Laboratories Announces Second Quarter Results 21IDEXX Laboratories Announces Second Quarter Results 22IDEXX Laboratories Announces Second Quarter Results 23IDEXX Laboratories Announces Second Quarter Results 24IDEXX Laboratories Announces Second Quarter Results 25IDEXX Laboratories Announces Second Quarter Results 26IDEXX Laboratories Announces Second Quarter Results 27IDEXX Laboratories Announces Second Quarter Results 28IDEXX Laboratories Announces Second Quarter Results 29IDEXX Laboratories Announces Second Quarter Results 30IDEXX Laboratories Announces Second Quarter Results 31IDEXX Laboratories Announces Second Quarter Results 32IDEXX Laboratories Announces Second Quarter Results 33
(Date:7/25/2014)... 25, 2014 As thousands of transvaginal ... courts, Bernstein Liebhard LLP notes that the Food & ... consumer advocacy group, Public Citizen, to order a global ... dated May 1, 2014, and released to the public ... for a ban on the marketing of all surgical ...
(Date:7/25/2014)... 2014 (HealthDay News) -- Babies seem to learn even ... the time women are 34 weeks pregnant, their unborn ... voice reciting a familiar nursery rhyme, the researchers report. ... sensory stimulation in the developing fetus," Charlene Krueger, nursing ... College of Nursing, said in a university news release. ...
(Date:7/25/2014)... vulnerable neurons and reduce motor deficits in a ... University School of Medicine have shown. , The ... Parkinson,s Disease . , The findings demonstrate that ... at sufficient levels and have beneficial effects when ... Previous studies of XPro1595 in animals tested more ...
(Date:7/25/2014)... American Society of Anesthesiologists (ASA) today announced the ... Learning Collaborative, a national initiative designed to improve ... More than 40 leading health care organizations ... collaborative, which will convene for the first time ... 25-26, in Schaumburg, Ill. , The PSH collaborative ...
(Date:7/25/2014)... 2014 Parkulture is proud ... and parkour instructor, Jared “JJ” Woods, will be competing ... American Ninja Warrior. The show will premiere on local ... will rerun on the new Esquire Network on Tuesday, ... resident, has been balancing careers as a professional stuntman ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 4Health News:Rhymes Reveal Evidence of Learning in the Womb 2Health News:Anti-inflammatory drug can prevent neuron loss in Parkinson's model 2Health News:ASA launches national Perioperative Surgical Home learning collaborative 2Health News:ASA launches national Perioperative Surgical Home learning collaborative 3Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 3
... /PRNewswire-USNewswire/ National Hospice and,Palliative Care Organization and National ... of Life Award(R). This prestigious award,celebrates innovation in ... depth, and scope., Award recipients were announced ... in San Diego. This year,s Award winners are:, ...
... available in German . Many sports ... country they are representing, not on a referee,s preference or ... color red for a uniform in competitive sports can actually ... scoring bias. , Psychologists Norbert Hagemann, Bernd Strauss and Jan ...
... transmission and the degree to which people are able to ... hope, have been overlooked in policies to tackle HIV/AIDS. ... (ESRC) argues that hope is a powerful tool in the ... years into the AIDS epidemic a medical vaccine for the ...
... Hospital & Research Center Oakland continues to lead the ... new medical journal focused on children and teenagers. ... Rehabilitation Department, is the founder and editor-in-chief of the ... . The quarterly journal released its second issue in ...
... Engineering Initiative Marks 12th Year of Summer ... ... undergraduate students,from colleges and universities, primarily across southwestern Pennsylvania,and the Pittsburgh ... the Pittsburgh Tissue Engineering Initiative (PTEI).,The goal of the program is ...
... who don,t know they have disease , , THURSDAY, Aug. ... blood sugar levels in people with diabetes could help identify ... statement released by a team of experts. , The ... cells have been exposed to in the previous 120 days, ...
Cached Medicine News:Health News:Circle of Life Awards Recognize Innovative End-of-Life Care Providers 2Health News:Circle of Life Awards Recognize Innovative End-of-Life Care Providers 3Health News:Red all over: how the color red affects a referee's judgment 2Health News:Hope: An overlooked tool in the battle against HIV/AIDS 2Health News:Children's Hospital Oakland publishes first of its kind pediatric rehabilitation journal 2Health News:Thirty-seven College Students Participate in Regenerative Medicine Summer Research Program 2Health News:Thirty-seven College Students Participate in Regenerative Medicine Summer Research Program 3Health News:Blood Sugar Test May Also Aid Diabetes Detection 2
... Ordering/Dispensing has gained recognition as the industry ... system. It enables opticians to place instant ... electronic communications technology. When used in conjunction ... frame tracers, lens shapes are automatically transmitted ...
... complete practice and business management software ... and ophthalmologists- It is designed for ... graphically rich and intuitive windows interface ... features and functionality- The multi-user version ...
The K-4500 automated hematology analyzer offers fast reliable test results of 18-parameter plus 3-histograms, valuable for effective diagnosis....
The XT-2000i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
Medicine Products: